AstraZeneca PLC Atacand Agreement with Cheplapharm Completed (4336C)
01 October 2018 - 4:00PM
UK Regulatory
TIDMAZN
RNS Number : 4336C
AstraZeneca PLC
01 October 2018
1 October 2018 07:00 BST
Agreement with Cheplapharm for rights to
Atacand in 28 European countries completed
AstraZeneca has completed an agreement with Cheplapharm
Arzneimittel GmbH (Cheplapharm) for the commercial rights to
Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose
combination of candesartan cilexetil and hydrochlorothiazide) in
Europe.
Under the terms of the agreement, AstraZeneca has received a
payment of $200 million from Cheplapharm. A time-bound payment of
$10 million as well as sales-contingent milestones will also be
payable. The present value of the upfront and time-bound payments
will be reported as Other Operating Income in the company's
financial statements in the third quarter of 2018.
AstraZeneca will continue to manufacture and supply Atacand and
Atacand Plus under a supply agreement and will continue to
commercialise the medicines in all markets where it still holds the
rights.
About Atacand
Atacand (candesartan cilexetil) is a selective, AT1 subtype
angiotensin II receptor antagonist blocker (ARB) that is indicated
for the treatment of hypertension and heart failure. Atacand is
also available in Europe as a fixed-dose combination of candesartan
cilexetil and hydrochlorothiazide (Atacand Plus). Atacand is
indicated for the management of hypertension in adults and
children/adolescents, as well as heart failure in adults. Atacand
Plus is indicated for the management of hypertension when
monotherapy is not sufficiently effective. Atacand was developed in
collaboration with Takeda. Each company holds the exclusive rights
to the product in certain markets. In other markets, Atacand is
co-marketed by both parties.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media Relations
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Cardiovascular; Metabolism +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors +44 203 749 5824
US toll-free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGREAENEDDXPEAF
(END) Dow Jones Newswires
October 01, 2018 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024